198 related articles for article (PubMed ID: 32237123)
1. FHIT
Da Silva J; Jouida A; Ancel J; Dalstein V; Routhier J; Delepine G; Cutrona J; Jonquet A; Dewolf M; Birembaut P; Deslée G; Polette M; Nawrocki-Raby B
J Pathol; 2020 Jun; 251(2):187-199. PubMed ID: 32237123
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic FHIT
Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
[TBL] [Abstract][Full Text] [Related]
3. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
[TBL] [Abstract][Full Text] [Related]
4. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
5. A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.
Gaudio E; Paduano F; Ngankeu A; Ortuso F; Lovat F; Pinton S; D'Agostino S; Zanesi N; Aqeilan RI; Campiglia P; Novellino E; Alcaro S; Croce CM; Trapasso F
Oncotarget; 2016 May; 7(21):29927-36. PubMed ID: 27166255
[TBL] [Abstract][Full Text] [Related]
6. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53.
Mascaux C; Martin B; Verdebout JM; Meert AP; Ninane V; Sculier JP
Eur Respir J; 2003 May; 21(5):753-8. PubMed ID: 12765416
[TBL] [Abstract][Full Text] [Related]
7. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer.
Andriani F; Perego P; Carenini N; Sozzi G; Roz L
Neoplasia; 2006 Jan; 8(1):9-17. PubMed ID: 16533421
[TBL] [Abstract][Full Text] [Related]
8. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
9. Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells.
Joannes A; Grelet S; Duca L; Gilles C; Kileztky C; Dalstein V; Birembaut P; Polette M; Nawrocki-Raby B
Mol Cancer Res; 2014 May; 12(5):775-83. PubMed ID: 24464917
[TBL] [Abstract][Full Text] [Related]
10. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
[TBL] [Abstract][Full Text] [Related]
11. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
12. FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
Wu DW; Lee MC; Hsu NY; Wu TC; Wu JY; Wang YC; Cheng YW; Chen CY; Lee H
Oncogene; 2015 May; 34(19):2505-15. PubMed ID: 24998847
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line.
Cavazzoni A; Petronini PG; Galetti M; Roz L; Andriani F; Carbognani P; Rusca M; Fumarola C; Alfieri R; Sozzi G
Oncogene; 2004 Nov; 23(52):8439-46. PubMed ID: 15361849
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
Cantor JP; Iliopoulos D; Rao AS; Druck T; Semba S; Han SY; McCorkell KA; Lakshman TV; Collins JE; Wachsberger P; Friedberg JS; Huebner K
Int J Cancer; 2007 Jan; 120(1):24-31. PubMed ID: 17019711
[TBL] [Abstract][Full Text] [Related]
15. Fhit regulates invasion of lung tumor cells.
Joannes A; Bonnomet A; Bindels S; Polette M; Gilles C; Burlet H; Cutrona J; Zahm JM; Birembaut P; Nawrocki-Raby B
Oncogene; 2010 Feb; 29(8):1203-13. PubMed ID: 19935706
[TBL] [Abstract][Full Text] [Related]
16. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
17. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
19. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.
Wu DW; Hsu NY; Wang YC; Lee MC; Cheng YW; Chen CY; Lee H
Oncogene; 2015 Apr; 34(16):2072-82. PubMed ID: 24909176
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
